Navigation Links
HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City
Date:11/25/2009

FRAMINGHAM, Mass. and SYDNEY, Nov. 25 /PRNewswire-FirstCall/ -- HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator and provider of less invasive, miniaturized circulatory support technologies revolutionizing the treatment of advanced heart failure, today announced that it is scheduled to make an investor presentation at the 21st Annual Piper Jaffray Health Care Conference at 8:00 am EST on Wednesday, December 2, 2009. The conference is being held at the New York Palace Hotel, December 1-2.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com. An archived replay of the presentation will also be available shortly after the presentation time for a period of 90 days.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or left ventricular assist devices, to treat Class IIIb and Class IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD(TM) pump, a small full-output circulatory support device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has received CE Marking for the HeartWare® Ventricular Assist System in the European Union. The device is currently the subject of a 150-patient clinical trial in the United States for a Bridge-to-Transplant indication.



For further information:
------------------------
U.S. Investor Relations
Matt Clawson
Allen & Caron Inc
Email: matt@allencaron.com
Tel: +1 949 474 4300


SOURCE HeartWare International, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare International Reports Third Quarter Revenues of $7.5 Million
2. U.S. FDA Authorizes Expansion to 40 Clinical Sites for HeartWare U.S. Bridge-to-Transplant Clinical Trial
3. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
4. Presentation of HeartWare Clinical Results
5. Chindex International to Present at Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference
7. Thoratec Presentation at Piper Jaffray Conference to be Webcast
8. Accumetrics to Present at the 21st Annual Piper Jaffray Health Care Conference
9. Ambit Biosciences Corporation Announces Presentations Profiling AC220 Clinical and Non-Clinical Data at 51st American Society of Hematology Annual Meeting
10. Echo Therapeutics to Present at the New York Society of Security Analysts 13th Annual Biotech and Specialty Pharmaceuticals Conference
11. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today announced that ... Bisaro as Impax,s President and Chief Executive Officer ... 27, 2017. Mr. Bisaro will succeed J. Kevin ... Chief Executive Officer since December of 2016. ... experience, Mr. Bisaro, 56, is an accomplished global business ...
(Date:3/27/2017)... , March 27, 2017 Invivotek, LLC, a ... in vivo pharmacology contract research organization (CRO), ... to its newly expanded preclinical research facility in ... provides a cleaner, renewable energy source to reduce costs ... Completion of the Genesis Solar Farm follows Invivotek,s recent ...
(Date:3/24/2017)... 2017  Zymo Research Corp., also known ... Inc., who designs, manufactures and distributes liquid ... teams Zymo Research,s DNA methylation detection and ... products with Hamilton,s high-throughput automation platforms. Zymo ... microbiomics and RNA isolation for use on ...
Breaking Medicine Technology:
(Date:3/27/2017)... London UK (PRWEB) , ... March 27, 2017 ... ... agility and ability to gain site attention and engagement over the household brands ... educational webinar will discuss how partnering with the right outsourcing payments ...
(Date:3/27/2017)... ... March 27, 2017 , ... Buzzies parent company, The TouchPoint Solution’s CEO ... Runway Foundation and UBS’ Project Entrepreneur. Mayo will present her pitch about the lifestyle ... Project Entrepreneur’s second annual venture competition ignites bold ideas by providing women access to ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... and conference coverage on veterinary medicine, announces the launch of Veterinarian’s Money Digest™, ... packaged with the April edition of American Veterinarian™. , “We look ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek ... to pursue the recent RNA methylation “gold rush” with their established portfolio of ... newfound characteristics of N6-methyladenosine, or m6A , RNA methylation has received a ...
(Date:3/27/2017)... Angeles, CA (PRWEB) , ... March 27, 2017 , ... ... men with prostate cancer, including all stages, is more than 95%. Once the cancer ... drastically to less than 30%. To find out how to avoid this latter group, ...
Breaking Medicine News(10 mins):